2,456 material Form 8-K filings that 2,073 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
MaxCyte agreed to acquire Akron BioProducts for total consideration of $151.8 million, including $105.0 million in cash at closing, 20,639,733 new common shares, and $20.0 million in deferred cash payments, with closing expected before the end of 2026. The same day it reported third quarter revenue up 49% and a narrower net loss, and raised full-year 2026 revenue guidance to at least $34.5 million, but the deal adds share dilution, a new credit facility and reduced expected year-end cash.
Q3 2026 total revenue was $10.2 million, up 49% from $6.8 million; net loss narrowed to $4.8 million from $12.4 million
Full-year 2026 total revenue guidance raised to at least $34.5 million, excluding the Akron acquisition
Akron terms: $105.0 million cash at closing, 20,639,733 shares, and $20.0 million deferred in two $10.0 million payments in 2028 and 2029
Funding includes a MidCap Financial facility of up to $75.0 million; closing is subject to HSR review and Nasdaq listing approval
TriSalus Life Sciences reported third-quarter 2026 revenue of $12.9 million, up 11.3% from a year earlier, and narrowed its operating loss to $7.7 million from $9.0 million. The company revised its full-year 2026 revenue guidance to $46 million to $48 million, which it said represents growth of about 2% to 6% over 2025, and said team productivity has ramped slightly slower than anticipated.
Q3 2026 revenue $12.9 million, up 11.3% year over year; gross margin 86.2% vs. 83.5%
Net loss attributable to common stockholders $8.9 million, or $0.15 per share, vs. $41.3 million, or $0.96 per share, in Q3 2025; prior-year figure included about $30.5 million tied to a preferred stock conversion
Full-year 2026 revenue guidance revised to $46 million to $48 million
Cash and cash equivalents $41.1 million at September 30, 2026
Coursera committed on November 9, 2026 to a workforce reduction plan tied to its May 2026 combination with Udemy, aiming to align costs and operations after the merger. The company expects to terminate about 10% of its global workforce and to incur $14 million to $17 million in charges, mostly severance and healthcare benefits, largely paid in cash during the fourth quarter of 2026 and the first half of 2027.
Plan to terminate approximately 10% of Coursera's global workforce
Estimated expenses of $14 million to $17 million, mainly termination benefits including severance and healthcare
Charges expected mostly in cash during Q4 2026 and first half of 2027; local law and consultation may extend timing
Company says it will disclose costs of broader merger synergy initiatives in future periodic reports
America's Car-Mart amended its credit agreement with Silver Point Finance and lenders to waive certain anticipated or existing events of default through September 7, 2026, and has since extended that date and related relief repeatedly. On November 9, 2026, the agent and lenders agreed to extend the Scheduled Termination Date and temporary relief on minimum liquidity and Collateral Coverage Ratio requirements through November 12, 2026, which signals the company is operating under short-term lender forbearance.
Credit Agreement dated October 30, 2025, amended by First Amendment and Limited Waiver with Silver Point Finance, LLC as Agent
Scheduled Termination Date extended from September 7, 2026 to November 9, 2026 and then to November 12, 2026
Temporary relief on minimum liquidity thresholds and minimum Collateral Coverage Ratio extended through November 12, 2026
PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial in myotonic dystrophy type 1, with mean splicing correction of 46.5% and no serious or severe adverse events reported. For the quarter ended September 30, 2026, the net loss widened to $19.4 million from $18.0 million a year earlier, and cash, cash equivalents and marketable securities were $104.8 million, which the company says will fund operations into 2028. The loss per share narrowed to $(0.28) from $(0.52), but weighted-average shares rose to 69,260,353 from 34,362,876, and the FDA's partial clinical hold on the FREEDOM2 study remains in place.
10 mg/kg cohort: mean splicing correction of 46.5% at Week 13; five of six participants above 20% and four above 50%
Net loss of $19.4 million for the quarter versus $18.0 million a year earlier; research and development expenses were $14.5 million versus $13.4 million
Cash, cash equivalents and marketable securities were $104.8 million at September 30, 2026, down from $148.5 million at December 31, 2025
12.5 mg/kg cohort is fully enrolled with results expected in the first half of 2027; FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical data expected in January 2027
AST SpaceMobile and Rakuten Group agreed to establish Rakuten AST, Inc., a joint venture to build a direct-to-device satellite network in Japan. The joint venture is expected to receive up to 148 billion yen (about $1 billion) in Japanese government support over roughly three years, and AST SpaceMobile will supply the satellites. The filing contains no revenue, profit, or financial impact figures for AST SpaceMobile itself.
Rakuten AST, Inc. agreed to be established November 6, 2026; planned establishment in November 2026
Rakuten Group holds 51% and AST SpaceMobile's Japanese subsidiary holds 49%
Expected up to 148 billion yen (about $1 billion) in support over about three years under Japan's J-LEO project
Planned commencement of domestic operations by the end of March 2029
Alliance Laundry reported third-quarter 2026 net revenues of $461 million, up 5% from a year earlier, and net income of $65 million compared with $33 million. It raised its full-year 2026 Adjusted EBITDA growth guidance to about 10%, the high end of its prior 8% to 10% range, while keeping revenue growth guidance at 6% to 7%. The company also repurchased $75 million of its common stock during the quarter.
Net revenues were $461 million, up 5% from $438 million; North America revenue rose 8% to $356 million.
Net income was $65 million versus $33 million; diluted EPS was $0.32 versus $0.19.
Adjusted EBITDA rose 14% to $127 million, with a 27.5% margin; a discrete tariff refund benefit helped results.
The company repurchased $75 million of stock and repaid $45 million of debt, reducing net leverage to 2.25x.
Kalaris Therapeutics reported a third-quarter net loss of $11.0 million, down from $11.9 million a year earlier, and $82.9 million in cash and marketable securities as of September 30, 2026. The company said a pilot manufacturer batch failed a release specification, pushing preliminary Phase 1b/2 data for TH103 in neovascular AMD to 2H 2027 and extending its cash runway into 2028.
Net loss was $11.0 million for the quarter ended September 30, 2026, versus $11.9 million a year earlier; net loss per share was $0.46 versus $0.64.
Research and development expenses were $8.3 million, down from $9.1 million; general and administrative expenses were $3.5 million, down from $3.6 million.
Cash, cash equivalents and marketable securities were $82.9 million, down from $118.0 million at December 31, 2025, and are expected to fund operations into 2028.
A new TH103 batch is now expected in Q2 2027, and technology transfer to KBI Biopharma was completed with test batches meeting target specifications.
LCI Industries said its board unanimously determined that a revised, unsolicited, non-binding proposal from Monomoy Capital Partners at $104.50 per share in cash is not a superior proposal and is not reasonably likely to lead to one. The board continues to recommend the pending merger with Patrick Industries, and shareholders will vote on it at a Special Meeting on November 18, 2026, which matters because a vote against the Patrick merger is not a vote for the Monomoy proposal.
Monomoy's revised proposal is $104.50 per share in cash, described by the board as a modest increase over its initial offer
Special Meeting of Shareholders scheduled for November 18, 2026
ISS and Glass Lewis both recommended that LCI shareholders vote FOR the Patrick merger
The companies remain on track to complete the transaction in the first half of 2027, subject to shareholder and regulatory approvals
At its Capital Markets Day on November 9, 2026, Entegris presented long-term targets of about 15% revenue CAGR, about 55% adjusted gross margin, about 35% adjusted operating margin and about 30% adjusted EPS CAGR. The Board authorized a share repurchase program of up to $500 million with no expiration date, and the company expects to raise its quarterly cash dividend by 10% beginning in the first quarter of 2027, subject to Board approval. The targets are long-term and not current results, but the buyback and dividend plan are concrete capital return steps for shareholders.
Board authorized repurchases of up to $500 million of common stock on November 8, 2026, with no expiration date.
Quarterly cash dividend expected to rise 10% beginning in the first quarter of 2027, subject to Board declaration.
Long-term targets: revenue CAGR of about 15%, adjusted gross margin of about 55%, adjusted operating margin of about 35%, adjusted EPS CAGR of about 30%.
Management says it expects to return about 50% of excess cash to shareholders.
Arbutus reported third-quarter 2026 net income of $59.1 million, driven mainly by a $67.3 million dividend from Genevant, compared with a net loss of $7.7 million a year earlier. Revenue fell to $0.3 million from $0.5 million, and the operating loss widened to $10.5 million from $8.7 million. The company ended the quarter with $337.5 million in cash and investments after returning $230 million to shareholders through a tender offer in early October.
Net income was $59.1 million, or $0.30 per basic and diluted share, for the quarter ended September 30, 2026, versus a net loss of $0.04 per share a year earlier.
Total revenue was $0.3 million, down from $0.5 million, and the operating loss was $10.5 million, compared with $8.7 million.
A $230 million Dutch Auction tender offer completed in early October 2026 bought 46 million shares at $5.00 per share, about 23% of shares outstanding as of September 29, 2026.
The FDA lifted the clinical hold on the AB-101 IND application in October 2026.
Energy Focus reported third quarter 2026 net sales of $4.8 million, up from $0.8 million a year earlier, and net income of $0.5 million, or $0.08 per share, compared with a net loss of $0.2 million in the third quarter of 2025. The company attributed the growth mainly to a Taiwan Uninterruptible Power Supply project with a new customer, and its forward-looking statements still cite substantial doubt about its ability to continue as a going concern.
Q3 2026 net sales were $4.8 million, up 481.2% year over year and up 28.1% from $3.7 million in Q2 2026.
Q3 2026 net income was $0.5 million, or $0.08 per diluted share, versus a Q2 2026 net loss of $0.9 million, or $(0.14) per share.
Nine-month 2026 net loss was $0.5 million, or $(0.08) per share, compared with $0.7 million, or $(0.12) per share, in the same period of 2025.
Cash was $3.3 million at September 30, 2026, including $0.9 million of short-term borrowings proceeds, versus $1.1 million at December 31, 2025.
Autolus reported third-quarter 2026 AUCATZYL net product revenue of $41.2 million, up from $21.1 million a year earlier, and now expects full-year 2026 AUCATZYL net product revenue at or above the upper end of $150 million, up from prior guidance. The company also reported a narrower net loss and said its cash is expected to fund operations into Q2 2028.
Q3 2026 net product revenue was $41.2 million versus $21.1 million in Q3 2025.
Gross margin was 57%, up from 55% in Q2 2026 and negative in Q3 2025.
Net loss was $55.1 million, compared with $79.1 million in the year-earlier quarter; loss per share was $(0.21) versus $(0.30).
Cash, cash equivalents and marketable securities were $248.4 million at September 30, 2026, up from $201.6 million at June 30, 2026, mainly from Perceptive senior secured note inflows.
CMC said CFO Paul Lawrence will retire effective January 15, 2027, and will stay on as Special Advisor to the CEO through June 30, 2027. Kenji Hashimoto, a former Amazon and American Airlines executive, joins as Senior Vice President and Deputy CFO on November 16, 2026, and is slated to become CFO on January 15, 2027, a planned succession rather than an unexpected departure.
Paul Lawrence notified the company on November 6, 2026, of his retirement as SVP and CFO, effective January 15, 2027; the filing says it is not the result of any disagreement with the company.
Kenji Hashimoto, 57, previously served as Managing Director at Global Infrastructure Partners from March 2024 to July 2025 and spent about 22 years at American Airlines.
Hashimoto's employment agreement provides a minimum annual base salary of $675,000, an annual cash bonus of up to 90% of base salary, and a target equity grant of up to 240% of base salary.
The employment agreement expires November 9, 2027, unless terminated or extended under its terms.
Scholar Rock agreed on November 9, 2026, to sell a Rare Pediatric Disease Priority Review Voucher to BioNTech US Inc. for $205 million in cash, payable at closing, which remains subject to customary conditions including the Hart-Scott-Rodino waiting period. The same day it reported third-quarter results, with its first ISEMBYLD product revenue of $0.6 million offset by a wider net loss of $107.2 million.
Buyer BioNTech US Inc. agreed to pay $205 million in cash at closing for the voucher, awarded after the September 11, 2026 FDA approval of ISEMBYLD
Q3 2026 net product revenue was $0.6 million, versus none in Q3 2025
Q3 2026 net loss was $107.2 million, or $0.81 per share, compared with a net loss of $102.2 million, or $0.90 per share, a year earlier
Cash, cash equivalents and marketable securities were $413.6 million as of September 30, 2026
Palladyne AI reported third-quarter 2026 revenue of $8.6 million, up from $0.9 million a year earlier, and raised the low end of its full-year 2026 revenue guidance to $25.0 million while keeping the top end at $27.0 million. The GAAP net loss widened to $12.0 million, or $0.25 per share, from $3.7 million, or $0.09 per share, in the prior-year quarter. Shareholders also face a 9% reduction in fully diluted shares after warrants and contingent shares expired on September 24, 2026.
Q3 2026 revenue was $8.6 million versus $0.9 million in Q3 2025, and up 48% sequentially.
GAAP net loss was $12.0 million ($0.25 per share) versus $3.7 million ($0.09 per share) a year earlier.
Full-year 2026 revenue guidance is now $25.0 million to $27.0 million, up from a prior low end, and backlog was $18.7 million as of September 30, 2026.
All 20.5 million warrants and 2.3 million remaining contingent merger consideration shares expired on September 24, 2026; cash, equivalents and marketable securities were $47.0 million.
Sionna Therapeutics reported a third-quarter 2026 net loss of $32.4 million, up from $20.3 million a year earlier, as research and development and general and administrative expenses rose. The company cut its workforce by about 46% in September 2026 and is not advancing SION-719 after its PreciSION CF Phase 2a trial missed its key activity endpoint, focusing instead on SION-451 + SION-2222, with a Phase 2 trial planned for the first quarter of 2027. Cash, cash equivalents and marketable securities were $249.8 million at September 30, 2026, which the company expects to fund operations into the second half of 2029.
Net loss was $32.4 million, or $0.72 per share, for the quarter ended September 30, 2026, compared with $20.3 million, or $0.46 per share, a year earlier.
R&D expenses were $22.0 million and G&A expenses were $12.8 million, up from $16.0 million and $7.8 million in the prior-year quarter.
Cash, cash equivalents and marketable securities totaled $249.8 million, down from $310.3 million at December 31, 2025.
The AscenSION CF Phase 2 proof-of-concept trial of SION-451 + SION-2222 is expected to start in the first quarter of 2027.
908 Devices reported third-quarter 2026 revenue of $19.0 million, up 35% from a year earlier, and a net loss from continuing operations of $4.6 million, down from $14.9 million. The company raised the low end of its full-year 2026 revenue guidance to $68.5 million to $70.0 million. A $11.0 million noncash reduction in contingent consideration expense helped narrow the loss, and the company reported no debt outstanding.
Q3 2026 revenue was $19.0 million, up from $14.0 million a year earlier; GAAP gross margin was 53%, unchanged from the prior year.
Operating expenses fell to $15.5 million from $23.7 million, mainly due to an $11.0 million noncash reduction in contingent consideration expense.
2026 revenue guidance is now $68.5 million to $70.0 million, up from $68.0 million to $70.0 million at the low end.
Cash and marketable securities were $99.1 million as of September 30, 2026, with no debt outstanding.
Enova International's Board authorized a new share repurchase program of up to $500 million, expiring June 30, 2028. The new program replaces the existing $400 million program, which would have expired June 30, 2027. The filing says the company is not obligated to buy any shares and the Board may change or end the program at any time.
New repurchase authorization of up to $500 million, described as the largest in Enova's history
Program expires June 30, 2028; replaces the $400 million program that would have expired June 30, 2027
Repurchases may be made in the open market or through privately negotiated transactions; no obligation to buy
Liquidia reported a third-quarter 2026 net loss of $236.3 million, or $2.64 per share, after a $389.7 million litigation settlement charge tied to its global settlement with United Therapeutics. Net product sales of YUTREPIA rose to $222.7 million from $51.7 million a year earlier, and non-GAAP adjusted EBITDA was $140.5 million. The settlement resolves all pending litigation with United Therapeutics, and Liquidia agreed to pay net $380.7 million in installments in 2026 and 2027.
Q3 2026 net loss of $236.3 million, or $2.64 per share, versus a net loss of $3.5 million, or $0.04 per share, in Q3 2025
Net product sales of $222.7 million, up 31% from Q2 2026 and up from $51.7 million in Q3 2025
Adjusted EBITDA of $140.5 million, the fifth consecutive quarterly increase; cash and cash equivalents were $396.1 million before settlement payments
Global settlement with United Therapeutics dated October 13, 2026, with Liquidia agreeing to pay net $380.7 million in 2026 and 2027
Harvard Bioscience filed an investor presentation dated November 2026 that reports third-quarter 2026 revenue of $22.2 million, up 8% from a year earlier, but adjusted EBITDA of $1.8 million, down from $2.0 million. The company lowered its full-year 2026 adjusted EBITDA growth outlook to (1)% to 4% from 6% to 10%, while its 3% to 5% revenue growth outlook is shown without a stated change.
3Q26 revenue $22.2 million vs $20.6 million in 3Q25 (up 8%); 3Q26 GAAP diluted loss per share $(0.58) vs $(0.28)
3Q26 adjusted EBITDA $1.8 million vs $2.0 million; adjusted EBITDA margin 7.9% vs 9.6%
FY26 adjusted EBITDA growth outlook lowered to (1)% to 4%, from 6% to 10%; FY26 revenue growth outlook 3% to 5%
4Q26 outlook: revenue $23.7 million to $25.5 million; adjusted EBITDA $3.8 million to $4.2 million
Janus International Group reported third quarter 2026 revenue of $213.1 million, down 2.8% year-over-year, and a net loss of $13.3 million, or $(0.10) per diluted share, compared with net income of $15.2 million a year earlier. The company also updated its full year 2026 guidance, which now projects Adjusted EBITDA of $127 million to $133 million, a 22.7% decline at the midpoint from the prior year.
Q3 2026 revenue was $213.1 million, down 2.8% year-over-year; self-storage revenue fell 5.0%.
Net loss was $13.3 million, or $(0.10) per diluted share, including an $18.3 million impairment of goodwill and intangible assets.
Adjusted EBITDA was $34.0 million, down 22.0% year-over-year, with a 16.0% margin.
2026 guidance: total revenue of $855 million to $865 million and Adjusted EBITDA of $127 million to $133 million.
WhiteFiber's indirect subsidiaries entered into a $300.0 million Term Loan Credit Agreement with Morgan Stanley Senior Funding and a lender group on November 9, 2026. No loans had been funded as of the filing date, and initial funding depends on conditions tied to the first 40 megawatts of the NC-1 data center in Madison, North Carolina. The loans are not guaranteed by WhiteFiber, Inc., but the financing adds debt tied to the project and includes covenants and a mortgage on the data center.
Facilities: $200.0 million initial term loan and $100.0 million delayed-draw term loan, both maturing on the fifth anniversary of initial funding
Interest at Term SOFR (2.00% floor) plus 6.00%, or base rate (3.00% floor) plus 5.00%, at the borrower's election
No loans funded as of the filing; initial funding is scheduled within 30 days after closing, with up to two 30-day extensions
Loans are not guaranteed by WhiteFiber, Inc.; the Operating Partnership must deliver an unsecured Phase 1 completion guarantee before initial funding
TransDigm reported fourth-quarter fiscal 2026 net sales of $2,988 million, up 23%, and EPS of $10.33, up 33%, while quarterly net income fell 4% to $586 million on higher interest and tax expense. The company also issued fiscal 2027 guidance calling for net sales of $11,950 million to $12,150 million and EPS of $42.06 to $42.91, which shareholders can compare against the fiscal 2026 results.
Q4 net sales $2,988 million, up 23% from $2,437 million; EPS $10.33, up 33% from $7.75.
Q4 net income $586 million, down $23 million or 4%; adjusted EPS $12.44, up 15% from $10.82.
Fiscal 2027 guidance: net sales $11,950 million to $12,150 million; EPS $42.06 to $42.91; adjusted EPS $47.09 to $47.94.
Company returned $943 million through buybacks in Q4 and $2.8 billion for fiscal 2026.
Venture Global reported third quarter 2026 revenue of $4.8 billion, up 43% from a year earlier, and net income attributable to common stockholders of $2.5 billion, compared with $429 million in the same quarter of 2025. The company raised its full-year 2026 Consolidated Adjusted EBITDA guidance to $10.0-$10.3 billion from $8.7-$9.1 billion, which is a positive signal for shareholders, though the company notes that natural gas prices could affect the outlook.
Q3 2026 revenue of $4.8 billion, up 43% from Q3 2025; diluted EPS of $0.96 versus $0.16
Net income attributable to common stockholders of $2.5 billion, versus $429 million a year earlier
2026 Consolidated Adjusted EBITDA guidance raised to $10.0-$10.3 billion from $8.7-$9.1 billion
Plaquemines Phase 1 began commercial operations on October 31, 2026; quarterly dividend of $0.04 per share payable December 31, 2026
Sono Group reported third-quarter 2026 net income of $0.6 million, compared with a net loss of $1.4 million in the third quarter of 2025, driven mainly by Bitcoin treasury income and a non-cash fair-value gain. For the first nine months, the company reported a net loss of $5.1 million, versus net income of $7.4 million a year earlier that included a $12.4 million fair-value gain, and management disclosed substantial doubt about its ability to continue as a going concern. Shareholders will vote on a proposed redomiciliation to Delaware at a meeting on December 11, 2026.
Q3 2026 net income was $0.6 million, versus a net loss of $1.4 million in Q3 2025; basic EPS was $0.32.
Nine-month 2026 net loss was $5.1 million, compared with net income of $7.4 million in the prior-year period.
General and administrative expenses fell 24% to $0.6 million in Q3 2026.
At September 30, 2026, cash was $0.5 million, Bitcoin was valued at $4.4 million, and $5.05 million of convertible debentures were outstanding, maturing January to April 2027.
Black Diamond Therapeutics reported updated Phase 2 data for silevertinib in frontline EGFR non-classical mutation lung cancer and said feedback from an October 1, 2026 FDA End of Phase 2 meeting supports a pivotal program. Its third-quarter financial results show a wider net loss than a year earlier, and cash, cash equivalents and investments declined to $102.0 million, which the company says funds operations into the second half of 2028.
Q3 2026 net loss was $10.0 million, compared with $8.5 million in Q3 2025; neither quarter had license revenue.
Nine-month 2026 net loss was $28.95 million, versus net income of $37.5 million in the first nine months of 2025, which included $70 million of license revenue.
Cash, cash equivalents and investments were $102.0 million at September 30, 2026, down from $128.7 million at December 31, 2025.
The planned global Phase 3 trial would enroll 300 patients and could start in the second quarter of 2027, with preliminary data anticipated in 2028.
Mercer and one non-operating subsidiary filed voluntary Chapter 11 petitions on November 9, 2026, in the U.S. Bankruptcy Court for the Southern District of Texas, to implement a joint prepackaged plan of reorganization. The plan would exchange about $1.275 billion of Senior Notes, and Mercer warns that equity holders may suffer a significant loss on their investment if the plan is confirmed.
Chapter 11 petitions filed November 9, 2026; Mercer's operating subsidiaries have not filed and will continue operating in the ordinary course.
Disclosure statement says funded debt would fall from about $1.6 billion at the Petition Date to about $700 million upon emergence.
Rights Offering of up to $400.0 million in new-money liquidity, with a New ABL Facility of up to $300.0 million.
Voting deadline is December 10, 2026; Mercer expects to complete the restructuring by the end of calendar year 2026 and cites possible delisting of its common stock from Nasdaq.
EPAM Systems entered a $500 million fixed dollar accelerated share repurchase agreement with UBS on November 9, 2026, under its $1.8 billion buyback authorization. The company received an initial delivery of 2,550,695 shares, about $400 million at the November 9 closing price, with final settlement expected in the first quarter of 2027. The final share count will depend on the volume-weighted average share price over the term of the agreement, less a discount.
Company pays $500 million to UBS under the ASR Agreement dated November 9, 2026
Initial delivery of 2,550,695 shares expected by November 10, 2026, worth $400 million at the November 9 closing price
Final settlement expected in the first quarter of 2027; final share count set on completion
Funded with cash on hand and borrowings under the existing credit facility
Community Health Systems' subsidiary CHS/Community Health Systems plans a private offer to exchange any and all of its roughly $1.24 billion of 6.875% notes due 2029 for new 10.25% senior secured notes due 2035, and to seek consents to remove substantially all restrictive covenants and certain events of default from the old notes' indenture. Supporting holders of about 52% of the old notes have agreed to tender, and the filing says the company expects to obtain the necessary consents. The offer is not yet launched and may not be completed on the stated terms.
Exchange consideration is $970 principal of new notes per $1,000 of old notes after the early tender deadline, or $1,000 with a $30 early tender premium if tendered by 5:00 p.m. New York time on November 23, 2026
Expiration date is December 10, 2026, unless extended or terminated
Supporting holders agreed to tender about $643.7 million of old notes, about 52% of the outstanding $1,244,476,000 principal
New notes mature January 15, 2035 and carry a 10.25% interest rate payable semi-annually
CKX Lands agreed on November 8, 2026, to accept a $1,000,000,000 cash investment from Jacobs Private Equity II, LLC and other investors. After closing, the investors would own about 99.78% of the company's common stock on an as-converted basis, and Brad Jacobs would become Chairman and Chief Executive Officer, so existing shareholders would hold a very small share of the company after the deal.
Investors would provide $1,000,000,000 in cash, with JPE becoming the controlling stockholder after closing.
Preferred stock convertible into about 219 million common shares at $4.57 per share, plus warrants for about 219 million shares, after a 4.1744380:1 reverse stock split.
Stockholders as of the holding company reorganization date would receive an aggregate cash dividend of $20,800,660, paid seven days later, only if the investment closes.
Closing requires stockholder approval and antitrust approvals; either party may terminate if closing has not occurred by June 30, 2027.
Sezzle furnished an investor presentation dated November 9, 2026, which it may use with investors starting that day. The presentation raises fiscal 2026 adjusted net income guidance to $190.0 million from $185.0 million and adjusted earnings per diluted share guidance to $5.45 to $5.50 from $5.25, and reports 955,000 active subscribers as of September 30, 2026. Adjusted figures are non-GAAP, and the company says prior guidance was not recast for tax effects, so the comparisons are not direct.
FY2026 adjusted net income guidance of $190.0 million, up from $185.0 million in the August update
FY2026 adjusted net income per diluted share guidance of $5.45 to $5.50, up from $5.25
955,000 active subscribers as of September 30, 2026, up 68.1% year over year
Investor presentation (Exhibit 99.1) dated November 9, 2026 may be used beginning that date
Globa Terra Acquisition Corp, a special purpose acquisition company, entered into a business combination agreement dated November 8, 2026 with Nature's Ledger Inc., a carbon markets and environmental assets company. The filing gives an indicated Nature's Ledger pre-money equity value of approximately $323.8 million, subject to adjustments, and a proposed PIPE financing, and completion depends on approvals, financing and other closing conditions. Shareholders also vote on a deadline extension at a November 9, 2026 meeting, where approval would trigger a $0.03 per public share trust contribution.
Business combination agreement dated November 8, 2026 with Nature's Ledger Inc.; indicated pre-money equity value of approximately $323.8 million, subject to adjustments
Structure includes a SPAC merger, a continuance under the ABCA, and an amalgamation that makes Nature's Ledger a wholly-owned subsidiary of publicly traded parent Pubco
Extension meeting on November 9, 2026 at 10:00 a.m. Eastern Time; approval triggers a $0.03 per public share sponsor trust contribution
Board may elect up to eight additional one-month extensions, potentially extending the deadline to July 9, 2027
BHAV Acquisition Corp, a special purpose acquisition company, entered into a Business Combination Agreement on November 3, 2026 with Nemi Corp., a Texas corporation with operations in India. The agreement would merge BHAV with a subsidiary of Nemi, leaving Nemi's successor company, Pubco, publicly traded, with Nemi's shareholders receiving 40,000,000 newly issued shares valued at $400 million. Completion depends on conditions including BHAV shareholder approval, regulatory approvals, registration statement effectiveness and Nasdaq listing approval.
Nemi shareholders would receive 40,000,000 newly issued Pubco shares, representing an aggregate value of $400 million.
Either party may terminate the agreement if the business combination has not closed by June 20, 2027, or a later extended date.
Closing is targeted for the first quarter of 2027, with Nemi planning to file a Form S-4 registration statement targeted for November 2026.
Nemi's founder and CEO, Anirudh Ravi Narayanan, has agreed to a two-year lock-up on his shares from closing.
Lantheus entered a definitive agreement on November 8, 2026 to sell its contract development and manufacturing organization business and its Springfield, New Jersey manufacturing facility to PharmaLogic Holdings Corp. The sale is subject to customary closing conditions, and PharmaLogic will also supply lutetium Lu 177 dotatate to Lantheus under a long-term supply agreement, which matters to shareholders as a sale of a business unit with an ongoing supply relationship.
Agreement signed November 8, 2026 to sell the CDMO business and Springfield, New Jersey facility to PharmaLogic
Lantheus will provide transition services to PharmaLogic immediately following closing
PharmaLogic's Agilera franchise will manufacture lutetium Lu 177 dotatate for Lantheus under a long-term supply agreement
The filing does not state a purchase price or expected closing date
Hallador Energy reported third-quarter 2026 results with total revenue of $130.3 million, down 11% from a year earlier but up 28% from the second quarter. The company posted a net loss of $4.5 million, compared with net income of $23.9 million a year earlier, and total debt rose to $551.9 million after a $600 million construction bridge loan tied to its Turtle Creek gas project, which it targets for a final investment decision before the end of 2026.
Q3 2026 total revenue was $130.3 million, down from $146.6 million in Q3 2025 and up from $101.5 million in Q2 2026.
Net loss was $4.5 million, versus net income of $23.9 million in Q3 2025 and a net loss of $15.2 million in Q2 2026.
Adjusted EBITDA was $17.3 million, compared with $24.9 million in Q3 2025.
Total debt rose to $551.9 million at September 30, 2026, from $45.0 million at June 30, 2026, after a $600 million senior secured construction bridge loan facility.
Microvast reported third-quarter 2026 revenue of $45.8 million, down 62.8% from $123.3 million a year earlier, and a net loss of $76.8 million, including $35.7 million of non-cash impairment charges. The company said its available cash is expected to be insufficient to meet obligations over the next twelve months, and its going concern doubt has not been alleviated, so shareholders face significant uncertainty about refinancing its debt.
Q3 2026 revenue was $45.8 million versus $123.3 million in Q3 2025; gross margin fell to 5.2% from 37.6%.
Q3 2026 net loss was $76.8 million, compared with a net loss of $1.5 million in Q3 2025.
Cash, cash equivalents and restricted cash were $124.4 million at September 30, 2026; $41.7 million of convertible bonds are due on or before January 31, 2027.
Net cash used in operating activities was $65.4 million for the nine months ended September 30, 2026.
DoubleVerify said it expects the merger under its August 6, 2026 agreement to close in the fourth quarter of 2026, subject to remaining closing conditions. Under the merger, DoubleVerify will survive as a wholly owned subsidiary of Neptune BidCo US Inc., so shareholders will be affected by the completion timing and terms of the deal.
Merger Agreement dated August 6, 2026, with Neptune BidCo US Inc. (Parent) and Wallace Merger Sub Inc. (Merger Sub)
Company expects closing during the fourth quarter of 2026, subject to satisfaction or waiver of remaining conditions
After the merger, DoubleVerify continues as the surviving corporation and a wholly owned subsidiary of Parent
Filing is made under Regulation FD and restates terms of a previously announced transaction
Summit Midstream reported third quarter 2026 net income of $15.9 million, compared with $5.0 million a year earlier, and raised its full-year 2026 Adjusted EBITDA guidance to $250 million to $260 million from $235 million to $255 million. Common stock dividends remain suspended, and the company's total net leverage ratio was approximately 3.9x as of September 30, 2026.
Q3 2026 net income $15.9 million vs. $5.0 million in Q3 2025; diluted EPS $0.58 vs. a loss of $0.13
Total revenues $183.0 million vs. $146.9 million a year earlier; Adjusted EBITDA $70.7 million vs. $65.5 million
2026 Adjusted EBITDA guidance raised to $250 million to $260 million from $235 million to $255 million
Common stock dividends remain suspended; Series A Preferred dividend payable to holders of record on December 1, 2026
Gores Holdings X said its unaudited financial statements for the three months ended September 30, 2025 should no longer be relied upon because of an error in calculating net loss per ordinary share. The restated basic and diluted net loss per share for that quarter is $(0.04), down from the previously reported $(0.65), while net income, the balance sheet and Trust Account amounts were not affected. Management also concluded that disclosure controls were not effective as of September 30, 2026 because of a material weakness in a review control.
Accretion of Class A shares was overstated by $27,471,919, with $31,069,071 reported instead of $3,597,152 for the three-month period.
Basic and diluted net loss per share for the three months ended September 30, 2025 is restated from $(0.65) to $(0.04).
Nine-month diluted Class B net loss per share is corrected from $(1.08) to $(1.10); the company says the error is not material.
The company has begun remediation, and WithumSmith+Brown has been briefed on the matter; the Q3 2026 Form 10-Q was filed November 9, 2026.
Tidewater reported third-quarter 2026 revenue of $360.4 million, up from $341.1 million a year earlier, and net income attributable to the company of $17.5 million, or $0.35 per diluted share, compared with a loss of $0.8 million a year earlier. The company also initiated 2027 revenue guidance of $1.70 to $1.75 billion and updated its 2026 revenue guidance to $1.43 to $1.44 billion, while closing a $500 million all-cash acquisition of Wilson Sons Ultratug Offshore.
Q3 2026 revenue of $360.4 million, up 5.3% from the second quarter of 2026
Q3 2026 net income of $17.5 million ($0.35 per diluted share), versus a $0.8 million loss a year earlier
Nine-month 2026 net income of $45.3 million, down from $114.8 million in the first nine months of 2025
2027 revenue guidance of $1.70 to $1.75 billion; 2026 revenue guidance updated to $1.43 to $1.44 billion
Reed's closed a private placement on November 9, 2026, issuing common stock to its majority stockholder, D&D Source of Life Holding, Ltd., for approximately $10.0 million in gross proceeds before offering expenses. The proceeds satisfied a requirement under the company's Senior Secured Loan and Security Agreement, as amended, to receive at least $10.0 million in cash equity contributions by November 20, 2026. The filing does not state the number of shares issued.
Issued common stock to majority stockholder D&D Source of Life Holding, Ltd. on November 9, 2026
Aggregate gross proceeds of approximately $10.0 million, before offering expenses
Met the loan agreement's requirement of at least $10.0 million in cash equity contributions due by November 20, 2026
Purchase Agreement was entered into October 28, 2026; its form was filed as Exhibit 10.1 to the November 3, 2026 8-K
JBS N.V. agreed to acquire Flora Produtos de Higiene e Limpeza S.A., a Brazilian personal care and household products company, from its controlling shareholder J&F, in a transaction valued at US$542 million including assumed debt. JBS also agreed to buy Canal Rural, a Brazilian agribusiness media company, for R$88.1 million, and both deals are related-party transactions to be paid mainly in JBS Class A shares, which would add to the share count and dilute existing holders.
Flora: R$2.968 billion purchase price (US$542 million enterprise value); equity consideration of US$367 million to be paid in JBS Class A shares and/or BDRs
Canal Rural: R$88.1 million purchase price, paid to J&F in Class A shares; the Ex-99.1 release gives a US$11 million transaction value
Share issuance is based on a reference price of R$66.82916 per share (US$12.20 30-day volume-weighted average), with about 31.4 million treasury shares, or 2.9% of the share count, cited in the market presentation
Both agreements were signed November 9, 2026, and the transactions are expected to close in December 2026, subject to customary closing conditions
Novanta reported third quarter 2026 results on November 9, 2026. GAAP revenue rose 23% to $305 million, while GAAP net income fell to $2 million from $10.7 million and GAAP diluted EPS fell to $0.05 from $0.30. The company also updated its full-year 2026 outlook, now expecting GAAP revenue of $1,135 million to $1,140 million, and said it closed its largest acquisition in company history, Riverpoint Medical.
Q3 2026 GAAP revenue was $305 million, up 23.1% from $247.8 million; Adjusted EBITDA rose 38.3% to $80.3 million.
GAAP operating income was $13.9 million versus $21.8 million a year earlier, and restructuring, acquisition, and related costs were $23.1 million.
Adjusted diluted EPS was $1.05, up 20.7% from $0.87; operating cash flow was $39.3 million versus $8.5 million.
For full-year 2026, the company now expects GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
Elmet Group reported third-quarter 2026 results for the period ended October 2, 2026, with revenue up 55.6% to $79.6 million and net income of $8.3 million, or $0.24 per diluted share, compared with $1.6 million, or $0.08, a year earlier. Gross margin rose to 31.3% and open order backlog reached a company record $347.4 million, though nine-month net income fell to $3.5 million from $4.0 million and the release gives no new guidance.
Q3 revenue was $79.6 million versus $51.1 million a year earlier; gross profit margin was 31.3% versus 21.7%.
Adjusted EBITDA was $17.0 million, or 21.3% of revenue, versus $7.4 million, or 14.5%, in Q3 2025.
Q3 net income was $8.3 million, or $0.24 per diluted share, versus $0.08 per diluted share a year earlier.
Nine-month net income was $3.5 million, or $0.10 per diluted share, versus $4.0 million, or $0.20, for the nine months ended September 30, 2025.
Effective November 1, 2026, Matthew DiCanio became President and Chief Executive Officer, William K. Newton moved to Executive Chairman, and Tanner Newton became Executive Vice President and Chief Financial Officer. The filing also details new employment agreements and restricted stock grants to named executive officers, which set severance and change-in-control terms for shareholders to weigh.
Matthew DiCanio: President and CEO, base salary $785,000, target bonus 125% of base salary
William K. Newton: Executive Chairman, base salary $550,000, target bonus 85% of base salary
Tanner Newton: EVP and CFO, base salary $425,000, target bonus 75% of base salary
Restricted stock granted November 3, 2026 vests equally over four years; DiCanio received 164,894 shares
AST SpaceMobile reported third quarter 2026 revenue of $42.3 million, up from $14.7 million a year earlier, and a net loss attributable to common stockholders of $132.4 million, or $0.44 per share, compared with $122.9 million, or $0.45 per share, in the third quarter of 2025. The company said it remains on target for its revenue guidance of $150.0 million to $200.0 million and cited about $1.0 billion in non-dilutive Japanese government funding for satellite manufacturing and launch.
Q3 2026 total revenue was $42.3 million versus $14.7 million in Q3 2025; nine-month revenue was $88.6 million versus $16.6 million
Net loss attributable to common stockholders was $132.4 million, or $0.44 per share, versus $122.9 million, or $0.45 per share, a year earlier
Company remains on target for 2026 revenue guidance of $150.0 million to $200.0 million
Cash, cash equivalents and restricted cash were approximately $3.2 billion as of September 30, 2026
QXO Chairman and CEO Brad Jacobs said on a November 9, 2026 conference call that September sales were much stronger than expected and that the company pre-released third-quarter adjusted EBITDA of $557 million on revenue of $4.9 billion, an 11.4% margin. He also said his family office will lead a $1 billion cash investment in NYSE American-listed CKX Lands, under which he would own a majority stake and become its chairman and CEO while remaining QXO's chairman and CEO.
Preliminary Q3 adjusted EBITDA of $557 million on revenue of $4.9 billion, an adjusted EBITDA margin of 11.4%
Companywide pricing improved 2.2% year-over-year in Q3; daily sales rose 5.4% year-over-year across the company in October
$1 billion CKX investment: $900 million from Jacobs Private Equity and $100 million from co-investors led by Heritage Partners, with CKX stockholder approval still required
Long-term target of $4 billion adjusted EBITDA by 2030 before additional acquisitions, versus roughly $1.75 billion in current consensus estimates
Forge Nano Holdings said it completed its merger with HzO, Inc. on November 4, 2026, with HzO surviving as a wholly owned subsidiary. HzO stockholders were issued Forge Nano common stock as consideration, and part of that stock is held back for twelve months to secure post-closing adjustments and indemnification. The filing adds dilution from the new shares, but it does not provide HzO financial results or the effect on Forge Nano's earnings.
Merger consideration is based on a $55.0 million base purchase price, plus or minus closing cash, working capital, indebtedness and expense adjustments, divided by $10.00 per share.
Forge Nano issued 5,772,645 shares at the Effective Time, with 1,533,795 Holdback Shares held back for twelve months.
Shares received by HzO stockholders are locked up until the earlier of six months after the Effective Time or when the stock closes at or above $12.00 for 20 of 30 trading days.
HzO's CFO Jason Savod and President and COO Rachael Lerebours signed employment agreements with Forge Nano effective after the Effective Time.
Mesa Laboratories reported fiscal second-quarter revenue of $62.3 million, up 2.6%, and net income of $4.3 million, up 75.3%, or $0.75 per diluted share versus $0.45 a year earlier. The company also issued its first fiscal 2027 guidance, calling for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, and authorized a share repurchase of up to $40 million.
Q2 revenue $62.3 million, up 2.6%; adjusted EBITDA $17.3 million, up 21.1%, or 27.8% of revenue
Fiscal 2027 guidance (year ending March 31, 2027): revenue $250 million to $255 million; adjusted EBITDA $66 million to $68 million
Board terminated its 2005 buyback program on November 4, 2026 and authorized up to $40 million in repurchases through December 31, 2028
Savings Plan announced October 13, 2026 expects total pre-tax restructuring charges of $2.6 million to $3.4 million, mainly in the second half of fiscal 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.